Interactions between immunoglobulin G molecules

Area of Science:

• Biochemistry
• Immunology
• Protein Engineering

Background:

• Therapeutic immune proteins, including intravenous immunoglobulin (IVIG) and monoclonal antibodies, are crucial for treating autoimmune diseases, cancer, and inflammatory conditions.
• High concentrations of these proteins, particularly IgG, can lead to self-aggregation, especially after prolonged storage.
• IgG aggregation increases immunogenicity and viscosity, posing significant challenges for clinical application.

Purpose of the Study:

• To investigate the mechanisms of IgG self-association in therapeutic protein preparations.
• To explore strategies for mitigating IgG aggregation and improving the stability and usability of immune globulin formulations.
• To identify key protein regions and interactions involved in IgG self-association.

Main Methods:

• Analysis of IgG aggregates in concentrated immune globulin solutions.
• Studies on idiotype-anti-idiotype interactions leading to IgG dimer formation.
• Site-directed mutagenesis of IgG contact residues to reduce self-aggregation.
• Characterization of mutant IgG antibodies for enhanced stability.
• Investigation of peptic pFc' fragment and C(H)3 domain interactions with Fc regions.
• Evaluation of hydroxyapatite chromatography for IgG aggregate removal.

Main Results:

• IgG self-association, forming networks and increasing viscosity, is driven by protein-protein interactions involving Fab and Fc portions.
• Site-directed mutagenesis of contact residues yielded more stable IgG antibodies with reduced aggregation.
• Specific fragments, like peptic pFc' and the C(H)3 domain, can prevent IgG aggregation by interacting with Fc regions.
• Hydroxyapatite chromatography shows potential for removing existing IgG aggregates.

Conclusions:

• IgG self-aggregation is a critical issue affecting the clinical utility of immune globulin preparations.
• Protein engineering approaches, including targeted mutagenesis and the use of specific fragments, can effectively reduce IgG aggregation.
• These strategies offer promising avenues for developing more stable and effective therapeutic immune protein formulations.